found that the activation of FGF19/FGFR4 leads to the creation of a complex within HCC, consisting of FGF receptor substrate 2 (FRS2) and growth factor receptor-bound protein 2 (GRB2), which subsequently activates the MAPK/ERK and PI3K/AKT pathways [38]. This evidence concerns the gene FGFR4 and hepatocellular carcinoma.